Previous studies reported that ABCC2 was involved in the imatinib sensitivity of CML And the above experiments indicate that ADORA2A-AS1 and miR-665 can regulate the expression of ABCC2. Here, ADORA2A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.